Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456788 | 0.93 | KDM4E (0.67) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| SCHEMBL29350135 | 0.91 | KDM4E (0.69) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| SCHEMBL30163040 | 0.91 | KDM4E (0.69) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| SCHEMBL29899307 | 0.91 | KDM4E (0.69) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| SCHEMBL23279 | 0.91 | KDM4E (0.69) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| SCHEMBL23861 | 0.91 | KDM4E (0.69) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| Hydrochloric Acid SCHEMBL10839750 | 0.89 | KDM4E (0.67) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| Bromide SCHEMBL1007533 | 0.89 | KDM4E (0.67) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| Hydrochloric Acid SCHEMBL10839755 | 0.89 | KDM4E (0.67) | KDM4EHSD17B10CDC25ACDC25BPOLB | |
| Hydrochloric Acid SCHEMBL9043607 | 0.89 | KDM4E (0.67) | KDM4EHSD17B10CDC25ACDC25BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244767-B2 | N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors | INNOVET ITALIA S.R.L. (IT) | 2007-07-17 | — | — | US | disclosed |
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | INNOVET ITALIA S.R.L. (IT) | 2005-03-24 | — | — | US | disclosed |
| EP-1115392-B1 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA SRL (IT) | 2002-12-11 | — | — | EP | disclosed |
| EP-1115392-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | Innovet Italia S.r.l. (IT) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000016756-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA S.R.L. (IT) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | CNR1, CNR2, GPR18 | KDM4E 2301/4885HSD17B10 3533/4885CDC25A 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.